GlassScriptPhysician profile
Manish Kumar Thakur
NPI 1093022386
$17,424.30
in general payments reported to CMS, 2019-2025
25 companies · $9,782 in 2025
The $9,782 reported for 2025 was more than what 80% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $31.79 · 2022: $48.90 · 2023: $15.93 · 2024: $7,342 · 2025: $9,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $733 · Travel and Lodging: $407 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,774.75 |
| Food and Beverage | $733.06 |
| Travel and Lodging | $407.23 |
| Education | $224.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $7,893.75 | 2024-2025 | Datroway |
| Janssen Biotech, INC. | $2,833.98 | 2019-2025 | Rybrevant |
| Regeneron Pharmaceuticals, INC. | $2,112.78 | 2024-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $2,040.00 | 2025 | Fruzaqla |
| Pfizer INC. | $1,661.96 | 2019-2025 | |
| Galvanize Therapeutics, INC | $315.01 | 2025 | Aliya System |
| Seagen INC. | $99.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $70.18 | 2019-2025 | Imfinzi |
| Array Biopharma INC | $42.74 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Puma Biotechnology, INC. | $41.99 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $41.59 | 2019-2020 | |
| Eisai INC. | $29.87 | 2024 | |
| Abbvie INC. | $28.97 | 2024 | |
| Jazz Pharmaceuticals INC. | $28.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.85 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.85 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.24 | 2019 | |
| Genentech USA, INC. | $19.63 | 2019 | |
| Gilead Sciences, INC. | $19.16 | 2019 | |
| Merck Sharp & Dohme LLC | $18.45 | 2020 | |
| Glaxosmithkline, LLC. | $18.34 | 2025 | Ojjaara |
| Celgene Corporation | $15.93 | 2023 | Reblozyl |
| Lilly USA, LLC | $11.56 | 2019 | |
| Emd Serono, INC. | $10.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Thakur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.